Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **gut barrier**—also known as the intestinal or gastrointestinal barrier—is a complex multicellular structure that separates the internal environment from luminal contents in the digestive tract. It is composed of several layers including a mucus layer rich in mucins secreted by goblet cells; a single layer of tightly joined epithelial cells; immune components such as those found in gut-associated lymphoid tissue; and underlying capillary endothelial cells. This system allows selective absorption of nutrients while preventing entry of pathogens, toxins, and antigens into circulation. The integrity and function of this barrier are maintained by tight junction proteins like ZO‑1, occludin, claudins; proper mucus production; balanced microbiota; and coordinated immune responses. Disruption or dysfunction—often referred to as “leaky gut”—can result from inflammation, metabolic disorders such as obesity or diabetes, infections, or dysbiosis. This leads to increased permeability with potential for bacterial translocation into systemic circulation causing chronic inflammation or sepsis. Therapeutic strategies focus on restoring tight junction integrity through drugs targeting signaling pathways like MLCK/NFκB/MAPK,[1] modulating microbiota with probiotics/prebiotics,[4] enhancing mucus production,[3] or using mucoprotectants.[6] The term “gut barrier protection” does not refer to a specific molecule/receptor but rather an overall physiological function involving multiple molecular targets within this system.[2][3][5] Therefore it is not considered a canonical therapeutic target itself but rather an endpoint influenced by interventions on various molecular components. Because "Gut Barrier Protection" is not a single molecule/receptor but describes a physiological process involving many targets—including tight junction proteins (e.g., ZO‑1), mucins (e.g., MUC2), receptors like Sphingosine 1-phosphate receptor 1—it should be flagged as incorrect for use where only discrete molecular entities are appropriate.[2][3][5]
Enhancement of tight junction protein expression[4][1]; Modulation of mucus production and secretion[3][6]; Regulation of immune cell activity in the gut-associated lymphoid tissue[2][4]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut barrier (intestinal barrier).